TTY Biopharm Co (台灣東洋藥品) yesterday gave an upbeat outlook on its earnings for this year, as the maker of “super generic” drugs further secures its leading position in the manufacture of oncology and anti-infective medicines. The local company is also tapping into the market for multiple sclerosis.
Last month, the Taipei-based company announced that with Netherlands-based 2-BBB Medicines BV, it has established a joint venture company, EnhanX Inc (殷瀚生技).
The joint venture is to develop 2B3-201, a neuro-inflammation treatment initially focused on people with multiple sclerosis (MS) who suffer acute relapses, the company said.
In addition, the partnership is expected to speed up the development and regulatory approval processes, TTY Biopharm said.
TTY Biopharm said that it would leverage its 20-year experience in developing specialized injectable liposomal formulations, as well as microsphere formulations, to control drug release in advancing 2B3-201 through its product pipeline.
The drug is a targeted therapy for MS that is designed to cross the blood-brain barrier — a highly selective semipermeable membrane that separates circulating blood from extracellular fluid in the central nervous system.
Conventional treatments for diseases such as MS require large dosing to penetrate the blood-brain barrier, resulting in severe side effects, the company said.
However, its proprietary fabrication technologies are able to prevent the triggering of unwanted autoimmune responses, which helps to overcome the blood-brain barrier and effectively deliver the medicine to the brain, the company said.
Apart from its controlling stake in the joint venture, TTY Biopharm said that it also controls the proprietary manufacturing process and therefore has a significant claim on any profits the drug makes.
The company’s net income in the first quarter dropped 21.35 percent year-on-year to NT$221 million (US$7.34 million), while sales rose 3.61 percent annually to NT$946 million over the period. Earnings per share were NT$0.89.
TTY Biopharm shares yesterday gained 0.49 percent to NT$102.5, outperforming the 0.05 percent fall of the TPEX, the local bourse for firms with small and medium capitalization, the market’s data showed.
Enhanced tax credits that have helped reduce the cost of health insurance for the vast majority of US Affordable Care Act enrollees expired on Jan.1, cementing higher health costs for millions of Americans at the start of the new year. Democrats forced a 43-day US government shutdown over the issue. Moderate Republicans called for a solution to save their political aspirations this year. US President Donald Trump floated a way out, only to back off after conservative backlash. In the end, no one’s efforts were enough to save the subsidies before their expiration date. A US House of Representatives vote
Nvidia Corp chief executive officer Jensen Huang (黃仁勳) on Monday introduced the company’s latest supercomputer platform, featuring six new chips made by Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), saying that it is now “in full production.” “If Vera Rubin is going to be in time for this year, it must be in production by now, and so, today I can tell you that Vera Rubin is in full production,” Huang said during his keynote speech at CES in Las Vegas. The rollout of six concurrent chips for Vera Rubin — the company’s next-generation artificial intelligence (AI) computing platform — marks a strategic
REVENUE PERFORMANCE: Cloud and network products, and electronic components saw strong increases, while smart consumer electronics and computing products fell Hon Hai Precision Industry Co (鴻海精密) yesterday posted 26.51 percent quarterly growth in revenue for last quarter to NT$2.6 trillion (US$82.44 billion), the strongest on record for the period and above expectations, but the company forecast a slight revenue dip this quarter due to seasonal factors. On an annual basis, revenue last quarter grew 22.07 percent, the company said. Analysts on average estimated about NT$2.4 trillion increase. Hon Hai, which assembles servers for Nvidia Corp and iPhones for Apple Inc, is expanding its capacity in the US, adding artificial intelligence (AI) server production in Wisconsin and Texas, where it operates established campuses. This
US President Donald Trump on Friday blocked US photonics firm HieFo Corp’s US$3 million acquisition of assets in New Jersey-based aerospace and defense specialist Emcore Corp, citing national security and China-related concerns. In an order released by the White House, Trump said HieFo was “controlled by a citizen of the People’s Republic of China” and that its 2024 acquisition of Emcore’s businesses led the US president to believe that it might “take action that threatens to impair the national security of the United States.” The order did not name the person or detail Trump’s concerns. “The Transaction is hereby prohibited,”
RSS